New Research for Immunotherapy Combinations with Paclitaxel Helping in Breast Cancer Fight

- FN Media Group Presents USA News Group News Commentary

VANCOUVER, British Columbia, July 21, 2020 /PRNewswire/ -- USA News Group – Researchers at the University of Cincinnati Cancer Center have found a potential new combination therapy for breast cancer that would integrate the body's immune system with targeted treatment for a protein that advances cancer. The UC study came on the heels of other announcements involving combination therapies, in particular with established chemotherapy drug paclitaxel, produced by Bristol-Myers Squibb (NYSE: BMY). Recent combination studies with paclitaxel have come from developers such as Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Athenex, Inc. (NASDAQ: ATNX), Merck KGaA (OTCPK: MKKGY), Merck & Co., Inc. (NYSE: MRK) and Pfizer Inc. (NYSE: PFE).

Paclitaxel's importance is understood around the world. Even the World Health Organization has it published on its Model List of Essential Medicines. However, the drug's efficacy may be greatly improved through its combination with other platforms.

Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) recently announced that the first patient was dosed in the company's Phase 2 study of a combination therapy to treat HR+/HER2- metastatic breast cancer (mBC). The therapy involves a combination of the company's proprietary pelareorep in combination with paclitaxel alone, and with paclitaxel and Bavencio from Merck KGaA (OTC: MKKGY)— which operates its biopharmaceutical business in the US and Canada as EMD Serono—and Pfizer Inc. (NYSE: PFE).

The study, known as BRACELET-1 is being conducted under a co-development agreement between all three companies.

This latest randomized BRACELET-1 study was designed to support the results of a prior successful Phase 2 trial that showed a near doubling of overall survival with pelareorep treatment.

Oncolytics Biotech's pelareorep success came from its ability to induce a robust anti-tumor immune response in an identical patient population (patients with HR+/HER2- mBC). The ability of pelareorep-induced immune responses to enhance anti- PD-L1 therapy will also be evaluated through the inclusion of the paclitaxel-pelareorep-avelumab combination therapy cohort.

Athenex, Inc. (NASDAQ: ATNX) has also worked to improve upon Taxol—the brand name given to paclitaxel by Bristol-Myers Squibb (NYSE: BMY).

In an effort to improve deliverability, Athenex is working to highlight the superiority of an oral paclitaxel called Abraxane over the intravenous version. Athenex claims that its oral version of paclitaxel produced less neuropathy (a paclitaxel side effect) than the IV version.

Last summer, Athenex released its pivotal Phase III study of combining oral paclitaxel with encequidar, showing the combo met the primary efficacy endpoint with statistically significant improvement over IV paclitaxel.

In May, Merck & Co., Inc. (NYSE: MRK) reported good results with the PD-1 inhibitor Keytruda, when given alongside chemotherapy. This treatment reportedly reduced the risk of disease progression or death by 35% compared to chemo alone, in its phase 3 KEYNOTE-355 trial, showing the drug was effective in previously untreated TNBC patients with high levels of the biomarker PD-1.

THE ONGOING FIGHT AGAINST BREAST CANCER

Roughly 90% of all breast cancer is estimated to be diagnosed at an early stage. Of that population, approximately 70% of all breast cancers are HR+, HER2-, the most common subtype of the disease.

The American Cancer Society has focused a lot of attention on researchers learning more about changes in cells that cause cancer, and the potential use of targeted therapies.

Biotechnology company Oncolytics Biotech Inc. is developing pelareorep, which is an intravenously delivered immuno-oncolytic virus.

The proprietary compound induces selective tumor lysis (where the tumor cells break down and die) and promotes an inflamed tumor phenotype. This in turn transforms "cold" tumors "hot" , through innate and adaptive immune responses to treat a variety of cancers.

Pelareorep has been in development for combinations with several of the world's other top selling anti-cancer drugs, including Bavencio from Merck KGaA and Pfizer.

Bavencio recently snagged the first-in-class designation for treating bladder cancer earlier this year. However, Pfizer has been pickier with its studies for breast cancer, including it swiftly pulling the plug on several Bavencio studies earlier this year. 

That didn't happen with Oncolytics Biotech's pelareorep.

Having now dosed the first patient in the BRACELET-1 study, new data is on the way. The study aims to validate T cell clonality as a biomarker of pelareorep response, and to enable advancement into a Phase 3 registrational study.

By combining with the checkpoint inhibitor therapy avelumab, Oncolytics Biotech is aiming to improve outcomes in metastatic breast cancer.

The immune-oncolytic virus platform is also being studied in combination with multiple other top selling cancer drugs, including Keytruda (also from Merck KGaA), Tecentriq from Roche, and Opdivo from Bristol-Myers Squibb.

With Tecentriq, pelareorep is being tested in combination with atezeolizumb, in the company's clinical program with the SOLTI WOO study in breast cancer. In late March, Oncolytics Biotech reported positive preliminary data from early findings in its AWARE-1 trial. 

According to preliminary findings announced back in 2019, the first three patients demonstrated immunohistochemically positive viral replication in the tumor mass following intravenous administration of pelareorep in combination with atezolizumab.

Of the three patients, two showed greater than 50% of the tumor cells infected. The drug was found to generate inflammation and T cell recruitment at the tumor site.

The BRACELET-1(BReast cAnCEr with the Oncolytic Reovirus PeLareorEp in CombinaTion with anti- PD-L1 and Paclitaxel) study is an open-label, phase 2, randomized study in patients with HR+/HER2-, endocrine-refractory metastatic breast cancer being conducted under a co-development agreement between Oncolytics, Merck, and Pfizer. PrECOG LLC, a leading cancer research network, is managing the study.

The study will take place at 20 trial sites and enroll 45 patients randomized into three cohorts. A three patient safety run-in will be conducted with patients receiving pelareorep, paclitaxel, and avelumab prior to randomization.

The primary endpoint of the study is overall response rate. Exploratory endpoints include peripheral and tumor T cell clonality, inflammatory markers, and safety and tolerability assessments.

Article Source: USA NEWS GROUP - Click Here to learn more about exciting opportunities in the Biotech Space

Disclaimer:

Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles.

While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

USA News Group is Source of all content listed above.  FN Media Group, LLC (FNM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with USA News Group or any company mentioned herein.  The commentary, views and opinions expressed in this release by USA News Group are solely those of USA News Group and are not shared by and do not reflect in any manner the views or opinions of FNM.  FNM is not liable for any investment decisions by its readers or subscribers.  FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNM was not compensated by any public company mentioned herein to disseminate this press release.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Media Contact Information:
FN Media Group, LLC
Media Contact e-mail:  
editor@financialnewsmedia.com 
U.S. Phone: +1(954)345-0611